Each tablet contains Torsemide 5 mg/10 mg/20 mg and Spironolactone 50 mg.

Torsinex Forte Tablets combine the potent loop diuretic Torsemide with the potassium-sparing diuretic Spironolactone to provide effective management of fluid overload and resistant hypertension. This dual-action formulation promotes the removal of excess sodium and water while minimizing potassium loss, helping reduce edema, improve symptoms of heart failure, and support blood pressure control in patients with conditions associated with secondary hyperaldosteronism.

Torsinex Forte Tablets are indicated for the treatment of edema associated with secondary hyperaldosteronism, resistant hypertension, congestive heart failure, and hepatic cirrhosis.

Torsemide is a loop diuretic that acts within the thick ascending limb of the loop of Henle, where it inhibits the Na⁺/K⁺/2Cl⁻ cotransporter. This action increases the urinary excretion of sodium, chloride, and water, reducing extracellular fluid volume and relieving edema. Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist that competitively blocks aldosterone at the sodium-potassium exchange sites in the distal convoluted renal tubule. It promotes sodium and water excretion while conserving potassium, thereby complementing the diuretic effect of Torsemide and reducing the risk of hypokalemia.

Treatment should generally be initiated with Torsemide 5 mg plus Spironolactone 50 mg once daily. Depending on the patient's clinical response and therapeutic requirements, the dosage may be increased to Torsemide 10 mg or 20 mg plus Spironolactone 50 mg, or as directed by the physician.

Torsinex Forte Tablets are contraindicated in patients with known hypersensitivity to Torsemide, Spironolactone, or any component of the formulation. Torsemide is contraindicated in patients with anuria and hepatic coma. Spironolactone is contraindicated in patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, or hyperkalemia.